<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39426052</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1275</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Atencion primaria</Title><ISOAbbreviation>Aten Primaria</ISOAbbreviation></Journal><ArticleTitle>Impact of COVID-19 on the prevalence of dyslipidemia in Ecuador: A cross-sectional study between 2017 and 2022.</ArticleTitle><Pagination><StartPage>103007</StartPage><MedlinePgn>103007</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aprim.2024.103007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0212-6567(24)00149-5</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine changes in the prevalence of dyslipidemias during the pre-COVID-19 and COVID-19 years in three regions of Ecuador.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional study. SITE: Quito, Guayaquil, and El Coca.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Adults with cholesterol, HDL, LDL, and triglyceride levels at primary care centers from January 2017 to December 2022.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Not applicable.</AbstractText><AbstractText Label="MAIN MEASUREMENTS" NlmCategory="METHODS">Data were obtained from five BIODIMED primary care centers. Cholesterol, HDL, LDL, and triglyceride levels were classified according to the ATP III guidelines. Dyslipidemia was considered present when one or more parameters exceeded specific thresholds. Sociodemographic variables and the year of examination were included as independent variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study analyzed 110,521 participants' laboratory results, where 65.3% were males and an average age of 38±12 years. The study spanned the Andean (72.4%), Coast (15.4%), and Amazonic region (12.3%). Pre-pandemic exams constituted 60.9% of the sample. The prevalence of dyslipidemia increased gradually from 43.1% in 2017 to 64.1% in 2022. Cholesterol levels, HDL, and LDL exhibited changes during the pandemic, with an increased risk of hypercholesterolemia, low HDL, and high LDL.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">During the COVID-19 pandemic, a notable increase in the prevalence of dyslipidemias, including hypercholesterolemia, high triglycerides, and high LDL, was determined across three regions in Ecuador.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Publicado por Elsevier España S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rivadeneira</LastName><ForeName>Josue</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universidad de La Frontera, Doctorado en Ciencias Médicas, Temuco, Chile; Zero Biomedical Research, Quito, Ecuador; Núcleo Milenio de Sociomedicina, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuenmayor-González</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Zero Biomedical Research, Quito, Ecuador; Universidad Central del Ecuador, Facultad de Ciencias Médicas, Quito, Ecuador.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jácome-García</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Zero Biomedical Research, Quito, Ecuador.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores-Lastra</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Zero Biomedical Research, Quito, Ecuador; Universidad De Especialidades Espíritu Santo, Facultad de Ciencias de la Salud-Nutrición, Guayaquil, Ecuador.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delgado</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Universidad de La Frontera, Doctorado en Ciencias Médicas, Temuco, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otzen</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Universidad de La Frontera, Doctorado en Ciencias Médicas, Temuco, Chile; Núcleo Milenio de Sociomedicina, Santiago, Chile; Universidad de La Frontera, Facultad de Medicina, Departamento de Especialidades Médicas, Temuco, Chile. Electronic address: tamara.otzen@ufrontera.cl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Aten Primaria</MedlineTA><NlmUniqueID>9111075</NlmUniqueID><ISSNLinking>0212-6567</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cross-sectional studies</Keyword><Keyword MajorTopicYN="N">Dislipidemias</Keyword><Keyword MajorTopicYN="N">Dyslipidemias</Keyword><Keyword MajorTopicYN="N">Ecuador</Keyword><Keyword MajorTopicYN="N">Estudios transversales</Keyword><Keyword MajorTopicYN="N">Hipercolesterolemia</Keyword><Keyword MajorTopicYN="N">Hipertrigliceridemia</Keyword><Keyword MajorTopicYN="N">Hypercholesterolemia</Keyword><Keyword MajorTopicYN="N">Hypertriglyceridemia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>18</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39426052</ArticleId><ArticleId IdType="doi">10.1016/j.aprim.2024.103007</ArticleId><ArticleId IdType="pii">S0212-6567(24)00149-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle>